SUANFARMA & WILLOW ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG
SUANFARMA and WILLOW BIOSCIENCES today jointly announced that they have, together with SUANFARMA’s CIPAN manufacturing site, completed the development and manufacturing process in pilot scale for the WILLOW-owned ingredient, Cannabigerol (CBG). The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
- SUANFARMA’ s CIPAN manufacturing site has significant expertise as a CDMO in fermentation and purification technologies under the highest standards of quality.
- WILLOW BIOSCIENCES is a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients using its FutureGrownTM
- WILLOW’S CBG, the company’s first functional ingredient for consumer care and health & wellness applications, is clinically tested to be safe and has been shown to act as a potent antioxidant, anti-inflammatory and anti-microbial.
After this successful technology transfer, development, and piloting, SUANFARMA and WILLOW BIOSCIENCES plan to broaden the relationship by offering an end-to-end synthetic biology solution and expanding their joint product portfolio. With this alliance, both companies will bring together their existing pharma and biotechnological capabilities for the production of ingredients, including anti-infectives and other Active Pharmaceutical Ingredients (APIs) and intermediates for Pharma, and natural ingredients designed for the Health & Wellness and Food & Beverage industries.
“CIPAN has proven itself a highly capable manufacturing partner with the efficient scaling and production of our first ingredient, CBG. We are excited to broaden the collaboration further to both offer an end-to-end solution to our customers while also expanding the portfolio of products with SUANFARMA” says Chris Savile, COO of WILLOW BIOSCIENCES.
“The development and piloting of this USP/DSP process in collaboration with WILLOW BIOSCIENCES is now completed and constitutes a very important milestone towards a robust, reliable, and efficient manufacturing process at industrial scale. This collaboration opens new business opportunities for both companies with important synergies.” says Daniel Rivero, Industrial Director of SUANFARMA.